GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (FRA:ISI) » Definitions » Other Gross PPE

Ionis Pharmaceuticals (FRA:ISI) Other Gross PPE : €206.5 Mil (As of Dec. 2024)


View and export this data going back to 1991. Start your Free Trial

What is Ionis Pharmaceuticals Other Gross PPE?

Ionis Pharmaceuticals's Other Gross PPE for the quarter that ended in Dec. 2024 was €206.5 Mil.

Ionis Pharmaceuticals's quarterly Other Gross PPE declined from Jun. 2024 (€225.6 Mil) to Sep. 2024 (€222.5 Mil) and declined from Sep. 2024 (€222.5 Mil) to Dec. 2024 (€206.5 Mil).

Ionis Pharmaceuticals's annual Other Gross PPE declined from Dec. 2022 (€198.1 Mil) to Dec. 2023 (€183.6 Mil) but then increased from Dec. 2023 (€183.6 Mil) to Dec. 2024 (€206.5 Mil).


Ionis Pharmaceuticals Other Gross PPE Historical Data

The historical data trend for Ionis Pharmaceuticals's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ionis Pharmaceuticals Other Gross PPE Chart

Ionis Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Gross PPE
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.19 33.73 198.15 183.56 206.50

Ionis Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 183.56 222.85 225.60 222.48 206.50

Ionis Pharmaceuticals Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


Ionis Pharmaceuticals Business Description

Traded in Other Exchanges
Address
2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.

Ionis Pharmaceuticals Headlines

No Headlines